A new paper sheds light on how the transcription factor BACH1 regulates the oxidative stress response, offering mechanistic insights into a key cellular pathway and potential target in oxidative stress-related diseases such as cancer, autoimmune disorders.

Novartis, @bioagelabs announce multi-year collaboration to discover novel targets for therapies that address age-related diseases and conditions.

Novartis has entered into a global license and collaboration agreement with @PTCBio for a Huntington’s disease program, currently in Phase II development, with the potential to become the first oral disease-modifying therapy for the disorder.

RT @NovartisNews: Novartis has acquired Kate Therapeutics, a preclinical stage biotechnology company focused on developing adeno-associated….

Novartis and @RatioTx have entered a license and collaboration agreement to advance a next-generation radioligand therapy to bring additional therapeutic options forward for patients with hard-to-treat cancer.

Novartis and Schrödinger have announced a multi-target research collaboration, and an expanded software agreement that will broaden Novartis access to Schrödinger’s computational predictive modeling technology and enterprise informatics platform.

Novartis, @MonteRosaTx announce an exclusive global development and commercialization license agreement to advance molecular glue degraders, including an investigational program currently in Phase 1 clinical development.

Novartis Biomedical Research and the @dundeeuni Drug Discovery Unit (DDU) are collaborating to advance drugs to help address global health challenges, including an antimalarial that targets dormant parasites, and an anti-viral for pandemic preparedness.

In @NatureMicrobiol, researchers describe a potential pediatric drug candidate for #cryptosporidiosis, a neglected disease that causes severe diarrhea, prolonged illness, and even death in young children and other vulnerable populations worldwide.

The President of Novartis Biomedical Research, @FionaHMarshall, talks about curiosity and collaboration, and her focus on developing “platforms for productivity” that build upon company successes to produce a robust portfolio of medicines for patients.

Novartis and Versant Ventures launch Borealis Biosciences, a discovery-stage biotech focused on developing next-generation RNA medicines for kidney diseases.

Novartis, Dren Bio sign collaboration agreement to discover, advance antibody-based immune cell engagers for certain cancers, building on Novartis efforts to explore a range of modalities and approaches to bring transformative therapies forward for patients.

Applications are being accepted for the Novartis Data Science Innovation Fellowship Program. If you are a recent PhD grad with a passion for #datascience & #AI and are interested in a career helping patients by advancing #drugdiscovery, apply by July 29.

Our researchers share a new approach for the potential treatment of #sicklecelldisease: using molecular glue degraders to break down a novel protein that suppresses fetal hemoglobin levels. Read their paper in @ScienceMagazine.

In @aplbioeng, Novartis researchers unveil a new device that enables high-throughput screening of stretched cells to better understand how they respond under mechanical stress and inform drug discovery. #mechanobiology.

Novartis, PeptiDream have entered into an agreement to expand their discovery collaboration aimed at identifying novel peptides for potential use in radioligand therapy and other contexts.

Yesterday, Novartis and @MedsforMalaria announced positive data from the CALINA study exploring a potential medicine formulated for the smallest babies with #malaria, for whom there is currently no evidence-based treatment.

Novartis has entered into a transaction with @ArvinasInc, including a global license agreement for the development and commercialization of an androgen receptor (AR) degrader which is in clinical development for prostate cancer.

Novartis has exercised its option to acquire IFM Due, advancing a collaboration started in 2019 to innovate novel STING antagonists with the potential to address unmet needs in inflammation-driven diseases.

RT @FionaHMarshall: I’m excited to share that we’re entering a strategic research collaboration with Isomorphic Labs to use state-of-the-ar….